Cargando…
Recurrent Glioblastoma: A Review of the Treatment Options
SIMPLE SUMMARY: Glioblastoma is the most common malignant brain tumor associated with a poor prognosis, with a median survival of 14 months. Despite initial treatment with surgery, radiotherapy, and chemotherapy, recurrence is the usual situation. Controversy remains over the best treatment strategy...
Autores principales: | Vaz-Salgado, Maria Angeles, Villamayor, María, Albarrán, Víctor, Alía, Víctor, Sotoca, Pilar, Chamorro, Jesús, Rosero, Diana, Barrill, Ana M., Martín, Mercedes, Fernandez, Eva, Gutierrez, José Antonio, Rojas-Medina, Luis Mariano, Ley, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487236/ https://www.ncbi.nlm.nih.gov/pubmed/37686553 http://dx.doi.org/10.3390/cancers15174279 |
Ejemplares similares
-
Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022) -
Current Landscape of Immunotherapy for Advanced Sarcoma
por: Albarrán, Víctor, et al.
Publicado: (2023) -
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
por: Albarrán, Víctor, et al.
Publicado: (2022) -
Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study
por: Vaz Salgado, María Angeles, et al.
Publicado: (2022) -
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)